NCT06187311View on ClinicalTrials.gov

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

PHASE4RecruitingINTERVENTIONAL
Enrollment

940

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Atrial FibrillationAnticoagulant Adverse Reaction
Interventions
DRUG

Rivaroxaban 20 MG

Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.

DRUG

Rivaroxaban 15 MG

Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.

Trial Locations (1)

02841

RECRUITING

Korea University Anam Hospital, Seoul

All Listed Sponsors
lead

Korea University Anam Hospital

OTHER